28 related articles for article (PubMed ID: 2430732)
1. A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.
Bordoloi D; Bhojnagarwala PS; Perales-Puchalt A; Kulkarni AJ; Zhu X; Liaw K; O'Connell RP; Park DH; Kulp DW; Zhang R; Weiner DB
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509287
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer
Wu Y; You X; Lin Q; Xiong W; Guo Y; Huang Z; Dai X; Chen Z; Mei S; Long Y; Tian X; Zhou Q
Front Pharmacol; 2021; 12():791269. PubMed ID: 35342388
[No Abstract] [Full Text] [Related]
3. Pre- and early postoperative GFAP serum levels in glioma and brain metastases.
Baumgarten P; Quick-Weller J; Gessler F; Wagner M; Tichy J; Forster MT; Foerch C; Seifert V; Mittelbronn M; Senft C
J Neurooncol; 2018 Sep; 139(3):541-546. PubMed ID: 29797180
[TBL] [Abstract][Full Text] [Related]
4. Human seminal proteinase and prostate-specific antigen are the same protein.
Waheed A; Hassan MI; Etten RL; Ahmad F
J Biosci; 2008 Jun; 33(2):195-207. PubMed ID: 18535354
[TBL] [Abstract][Full Text] [Related]
5. The role of prostatic specific antigen in monitoring prostatic cancer and its prognostic importance.
Arai Y; Yoshiki T; Oishi K; Takeuchi H; Yoshida O
Urol Res; 1990; 18(5):331-6. PubMed ID: 1701586
[TBL] [Abstract][Full Text] [Related]
6. Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein.
Hara M; Kimura H
J Lab Clin Med; 1989 May; 113(5):541-8. PubMed ID: 2654306
[TBL] [Abstract][Full Text] [Related]
7. Three predominant prostatic proteins.
Abrahamsson PA; Lilja H
Andrologia; 1990; 22 Suppl 1():122-31. PubMed ID: 1720287
[TBL] [Abstract][Full Text] [Related]
8. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
[TBL] [Abstract][Full Text] [Related]
9. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
[TBL] [Abstract][Full Text] [Related]
10. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
Shinoda I
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
[TBL] [Abstract][Full Text] [Related]
11. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.
Fuse H; Umeda K; Mizuno I; Katayama T
Int Urol Nephrol; 1991; 23(5):455-63. PubMed ID: 1718922
[TBL] [Abstract][Full Text] [Related]
12. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
13. Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.
Siddall JK; Shetty SD; Cooper EH
Clin Chem; 1986 Nov; 32(11):2040-3. PubMed ID: 2430732
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
